GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: This compound is claimed as an allosteric inhibitor of BCR:ABL oncogene fusions [4]. It belongs to the STAMPi class that bind to the ABL myristate pocket rather than the ATP active site. STAMP inhibitors are designed for the treatment of chronic myeloid leukemia with BCR:ABL rearrangements, particularly for malignancies that acquire ABL resistance mutations to previous kinase inhibitor therapies.
We suspect that this might be Hansoh Pharmaceutical's lead oral STAMPi HS-10382 (subsequently becoming TERN-701; Terns Pharmaceuticals), as this is the compound claimed in Hansoh's crystallisation patent CN120981465A [2]. TERN-701 was granted FDA orphan drug designation in March 2024. In spring 2026 Merck acquired Terns and its assets. We await official disclosure of the TERN-701/HS-10382 structure to confirm/disprove our prediction. |
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
Database Links ![]() |
|
| BindingDB Ligand | 707185 |
| PubChem CID | 172538807 |
| Search Google for chemical match using the InChIKey | IRJUOLZMONEIKV-FAYKFVSFSA-N |
| Search Google for chemicals with the same backbone | IRJUOLZMONEIKV |
| UniChem Compound Search for chemical match using the InChIKey | IRJUOLZMONEIKV-FAYKFVSFSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | IRJUOLZMONEIKV-FAYKFVSFSA-N |